Public's Intended Uptake & Views on Organization of Esophageal Cancer

Status Recruiting

Clinical Trial Summary

Rationale: Research on novel methods to screen for esophageal adenocarcinoma (EAC) has expanded. Insight into individuals' drivers and barriers to attend screening is essential to tailor a potential new screening policy to their preferences. Public preferences should also be considered on the organizational level to guarantee client-centered decision-making in the design of the screening process. Objective: This study will examine Dutch individuals' intended uptake of EAC screening, including factors that predict uptake, and their views on its organization. Study design: Cross-sectional population-based survey. Study population: Dutch individuals aged 45-75 years. The required sample size is 2088 and 8350 individuals will be invited based on an assumed participation rate of 25%. Methods: Eligible individuals will be selected from the Dutch population registry (BRP) using simple random sampling. Invitations will be sent by postal mail with participants being directed to a digital survey. Main study parameters/endpoints: The primary outcome of the study is the intended uptake of EAC screening (strong vs weak). Secondary study endpoints are the perceived need for consultation, perceived need for general education campaigns, acceptability of risk stratification scenarios, and acceptability of using health care resources for EAC screening. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects will not directly benefit from participating in this study. Nonetheless, participating in this study is not associated with any healthcare risks and the burden for the subjects is very low. The survey has a low burdensome nature and will take approximately 15 to 20 minutes to complete. All data will be pseudonymized, refusal to fill out the survey or desire to withdraw from the study will not have any consequences for the invited subject.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05690958
Study type	Observational
Source	Radboud University Medical Center
Contact	Jasmijn D Sijben, drs
Phone	+31629061198
Email	jasmijn.sijben@radboudumc.nl
Status	Recruiting
Phase
Start date	February 13, 2023
Completion date	July 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03554356` - Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)	N/A
Completed	`NCT03015389` - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Completed	`NCT03434834` - OCT Pilot in Esophagus	N/A
Terminated	`NCT04642690` - Nitrates and IL-8 in Barrett's Esophagus
Completed	`NCT03468634` - Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy	N/A
Recruiting	`NCT02310230` - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy	N/A
Completed	`NCT00217087` - Endoscopic Therapy of Early Cancer in Barretts Esophagus	Phase 2
Completed	`NCT02284802` - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy	N/A
Recruiting	`NCT05530343` - Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance	N/A
Active, not recruiting	`NCT04151524` - Classification of Adenocarcinoma of the Esophagogastric Junction
Completed	`NCT00955019` - Novel Method of Surveillance in Barrett's Esophagus	Phase 2
Terminated	`NCT00386594` - Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus	N/A
Completed	`NCT00576498` - Novel Imaging Techniques in Barrett's Esophagus	N/A
Completed	`NCT02688114` - Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus	N/A
Recruiting	`NCT06071845` - Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples	N/A
Completed	`NCT02560623` - A Minimally-Invasive Sponge on a String Device for Screening for Barrett's Esophagus	N/A
Recruiting	`NCT05056051` - Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus	N/A
Recruiting	`NCT04001478` - Non-invasive Testing for Early oEesophageal Cancer and Dysplasia
Completed	`NCT03859557` - The Evaluation of Patients With Esophageal and Foregut Disorders With WATS (Wide Area Transepithelial Sample With 3-Dimensional Computer-Assisted Analysis) vs. 4-Quadrant Forceps Biopsy
Completed	`NCT04587310` - Does Laparoscopic Sleeve Gastrectomy Lead to Barrett's Esophagus, 5-year Esophagogastroduodenoscopy Findings: A Retrospective Cohort Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Public's Intended Uptake and Views on Organization of Esophageal Cancer Screening — ACCEPT-survey

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms